INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 42h ago
House PTR2h ago
SEC 13F2h ago
Robinhood Chain2h ago

Most active filers · 30d

  1. 01Kurtz George0B / 237S237 trades$57.36M
  2. 02SPSaba Capital Management, L.P.77B / 19S · 11 late96 trades$25.89M
  3. 03SJSheena Jonathan0B / 57S57 trades$3.61M
  4. 04ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  5. 05AJAllaire Jeremy0B / 50S50 trades$4.26M
  6. 06Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  7. 07SLSpeiser Michael L0B / 35S35 trades$14.00M
  8. 08RARothblatt Martine A0B / 33S33 trades$5.50M
  9. 09RJRubinstein Julie0B / 32S32 trades$5.48M
  10. 10CECrimmins David Edward0B / 31S31 trades$723K

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 631 insiders$417K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 108 insiders$40.91M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

71,432 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
11
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$27K
600 sh
Feb 2, 2026Feb 4, 2026
Page 1350 of 1786
← PrevNext →
traded Feb 2, 2026
+2d
SEC Form 4

Evidence

11
HK
Holleran KevinDirector, President and CEO
HAYWHayward Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$841K
52.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

11
CN
Chandhok NikhilChief Product & Tech. Officer
CRCLCircle Internet Group, Inc.
Tax withholding
F$926K
14.5K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

11
TH
Tarbert HeathPresident
CRCLCircle Internet Group, Inc.
Tax withholding
F$511K
7,989 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

10
RM
Rucci Carolyn M.SVP, Chief Legal Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$23K
16.8K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

10
RM
Rucci Carolyn M.SVP, Chief Legal Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$35K
25.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

10
AL
Alpern Paul LVP and General Counsel
AIPArteris, Inc.
Open-market sale · 10b5-1 plan
SELL$77K
5,000 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

10
RM
Rucci Carolyn M.SVP, Chief Legal Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$38K
27.5K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

10
MC
Malabre Richard CSVP, Chief Accounting Officer
AKBAAkebia Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$19K
13.4K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
AM
Adamchak MarkPrincipal Accounting Officer
BNGOBionano Genomics, Inc.
Grant or award
A—
10.9K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
KA
Kleczynski Robert ASVP, Controller & Tax
EXCEXELON CORP
Option exercise
M—
7,019 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
SK
Shaikh KashifDirector, President and CEO
PENGPenguin Solutions, Inc.
Grant or award
A—
238.2K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
CJ
Conway Kevin JohnChief Financial Officer
GBIOGeneration Bio Co.
Option exercise
M—
235 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
GW
Go WilliamChief Medical Officer
JANXJanux Therapeutics, Inc.
Grant or award
A—
44.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
CJ
Conway Kevin JohnChief Financial Officer
GBIOGeneration Bio Co.
Tax withholding
F$406
72 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
FD
Feierstein Matthew DavidPresident
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$121K
10.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
BS
Bohen SeanDirector, PRESIDENT AND CEO
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
850.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
LF
Link David ForrestDirector
APPNAPPIAN CORP
Grant or award
A—
771 sh
Feb 4, 2026Feb 4, 2026
traded Feb 4, 2026
+0dSEC Form 4

Evidence

9
KA
Kleczynski Robert ASVP, Controller & Tax
EXCEXELON CORP
Grant or award
A—
5,673 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
SS
Stiles Spencer SPresident and COO
SYKSTRYKER CORP
Option exercise
M—
13.8K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

9
HY
Howze YalondaINTERIM CEO & PRESIDENT
GBIOGeneration Bio Co.
Option exercise
M—
1,673 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
FD
Feierstein Matthew DavidPresident
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$102K
9,280 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

9
BS
Bohen SeanDirector, PRESIDENT AND CEO
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
275.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
KA
Kleczynski Robert ASVP, Controller & Tax
EXCEXELON CORP
Option exercise
M—
1,474 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
GF
Ghingo John FDirector, President
HRLHORMEL FOODS CORP /DE/
Grant or award
A—
201.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
JM
Jones Jeanne MEVP, CFO, Audit & Risk
EXCEXELON CORP
Option exercise
M—
5,197 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
GW
Go WilliamChief Medical Officer
JANXJanux Therapeutics, Inc.
Grant or award
A—
154.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
CC
Cowan ChadChief Scientific Officer
IPSCCentury Therapeutics, Inc.
Grant or award
A—
135.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
KA
Kleczynski Robert ASVP, Controller & Tax
EXCEXELON CORP
Option exercise
M—
1,474 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
SR
Shrewsbury RondaDirector
SRCE1ST SOURCE CORP
Grant or award
A$16K
243 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

9
CS
Christian Matthew SeanPresident, Architectural Serv
APOGAPOGEE ENTERPRISES, INC.
Tax withholding
F$14K
360 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
DV
Dixon Jonathan V.GENERAL COUNSEL
BNGOBionano Genomics, Inc.
Grant or award
A—
26.1K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
JM
Jones Jeanne MEVP, CFO, Audit & Risk
EXCEXELON CORP
Option exercise
M—
24.7K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
JM
Jones Jeanne MEVP, CFO, Audit & Risk
EXCEXELON CORP
Option exercise
M—
6,485 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
MC
Monroe CarolynSVP - Title Insurance
ORIOLD REPUBLIC INTERNATIONAL CORP
Option exercise
M—
16.5K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
PC
Perkins Tandra CDirector
CMCCOMMERCIAL METALS Co
Grant or award
A$1,125
14 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
PG
Peterson Timothy GeorgeEVP Chf Cust & Tech Officer
EXCEXELON CORP
Grant or award
A—
11.3K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
KJ
Kim Peter Sung-JipSVP & GM Industrial Business
LFUSLITTELFUSE INC /DE
Option exercise
M—
5,488 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
SK
Shaikh KashifDirector, President and CEO
PENGPenguin Solutions, Inc.
Grant or award
A—
238.2K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
BO
Biebuyck OlivierPresident, Fab Tech
ESABESAB Corp
Option exercise
M—
1,232 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence